Famciclovir update. Chronic hepatitis B.

Author(s): Young CL

Affiliation(s): SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania 19426-0989, USA.

Publication date & source: 1999, Adv Exp Med Biol., 458:23-7.

Publication type: Review

The growing body of preclinical data, as well as clinical data from the phase II doseranging study in immunocompetent patients and from liver transplant recipients participating in the compassionate use program, indicates that famciclovir offers the promise of safe and convenient oral treatment of chronic hepatitis B infection. The results of phase III pivotal studies are eagerly awaited. Denavir is a trademark of SmithKline Beecham plc.